Lycopene cancer study
This article was originally published in The Tan Sheet
Executive Summary
Consumption of tomato products, but not lycopene alone, inhibited the onset of prostate cancer in rats, reports a study published in the Nov. 5 Journal of the National Cancer Institute. Steven Clinton, MD/PhD, et al. found male rats on tomato-based diets demonstrated lower mortality rate than rats in control and lycopene groups. Results suggest "tomato phytochemicals and diet restriction may act by independent mechanisms" to reduce prostate cancer risk. Supplement marketer American Longevity filed a petition in June for approval of cancer risk reduction claims on lycopene, tomatoes and tomato-based products (1"The Tan Sheet" June 9, 2003, p. 17)...
You may also be interested in...
Lycopene Health Claim For Cancer Risk Reduction Requested In Petition
There is significant scientific agreement among experts that lycopene is an "effective modifier of the risk of certain cancers," supplement marketer American Longevity states in a June 4 health claim petition to FDA
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.